Abstract
Sharikadze O.V.
Background. This study determined the efficacy of sublingual allergen–specific immunotherapy (SLIT) in Ukrainian children younger than 5 years of age with allergic rhinitis and bronchial asthma sensitized to house dust mite allergens. Methods. A cohort prospective study was conducted over a two years period with assessment of the sensitization towards inhalant allergens, measured in-vivo by wheal size and number of positive reactions on the standard skin prick test (SPT). SPSS was used to analyse any statistical correlation. Results. A total of 125 atopic asthma or/and allergic rhinitis with the mean age of 4.11 ±0.83 who were sensitized to house dust mites Dermatophagoides pteronyssinus and/or Dermatophagoides farina were included. 47 children received two-years SLIT to treat house dust mite allergies using standardized extract of sublingual allergens containing a mixture of house dust mites (Der. pteronyssinus and Der. farinae) in the correlation of 1(0,175 НЕР):1(0,175 НЕР) (Diater, Spain). These patients were mono-sensitized with Der. pteronyssinus and Der. farinae or were SPT poly-sensitized, but these patients only had house dust mite allergy symptoms. In this group the assessment of clinical efficacy of SLIT showed the significant differences in VAS before treatment and 6 months after its receiving. The symptom “nasal obstruction” was assessed as 2.3±-1.6 points at the beginning of the therapy, and the data reduced almost twice (1.3±-1.1); Р <0,05 after 6 months of SLIT; then (12 and 24 months) it decreased to 0.91±0.9 and 0.34±0.5; Р <0,01, correspondingly. Conclusion. This study has shown that using of SLIT in atopic asthma or/and allergic rhinitis children under 5 year sensitized to house dust mites is an effective and safe treatment method and allows to quickly (over the first 6 months of SLIT) control the symptoms. The data of comparative analysis in the group of patients who didn’t receive SLIT has pointed to high frequency of disease symptom occurrence after the end of baseline therapy.
KeyWords: sublingual allergen-specific immunotherapy, children, bronchial asthma, allergic rhinitis, sensitization, allergens, Diater
ОСОБЛИВОСТІ ЛІКУВАННЯ ДІТЕЙ ДОШКІЛЬНОГО ВІКУ, СЕНСІБІЛІЗОВАНИХ ДО АЛЕРГЕНІВ ДОМАШНЬОГО ПИЛУ
Шарикадзе О.В.
Це дослідження визначило ефективність сублингвально алерген-специфічної імунотерапії (SLIT) українських дітей молодше 5 років з алергічним ринітом та бронхіальною астмою, сенсибілізованих до алергенів пилових кліщів. Методи. Проспективне дослідження когорти проводилося протягом двох років з оцінкою сенсибілізації до інгаляційних алергенів, виміряної in-vivo за розміром пухирів і кількості позитивних реакцій на стандартному тесті на шкірі (SPT). Для аналізу статистики використовувався пакет SPSS. Результати. Обстежено 125 дітей (середній вік 4,11 ± 0,83 років) з атопічною астмою та/або алергічним ринітом, які були сенсибілізовані до домашніх пилових кліщів Dermatophagoides pteronyssinus та/або Dermatophagoides farina. 47 дітей отримали дворічний курс SLIT з використанням стандартизованого екстракту сублінгвальних алергенів, що містять суміш кліщів домашнього пилу (Der. Pteronyssinus і Der. Farinae) в співвідношенні 1 (0,175 НЕР): 1 (0,175 НЕР) (Діатер, Іспанія). Пацієнти були моносенсібіровани Dermatophagoides pteronyssinus і / або Dermatophagoides farina або були полісенсібілізовані (за SPT), однак симптоми розвивалися тільки на домашній пил. У цій групі оцінка клінічної ефективності SLIT показала значні відмінності до лікування і через 6 місяців після його отримання. Симптом «носової обструкції» оцінювався як 2,3 ± 1,6 бала на початку терапії і зменшувалися майже в два рази (1,3 ± 1,1); Р <0,05 після 6 місяців SLIT. Потім (12 і 24 місяці) він знизився до 0,91 ± 0,9 і 0,34 ± 0,5; Р <0,01, відповідно. Висновок. Дослідження показало, що використання SLIT при атопічній астмі та/або алергічному риніті у дітей до 5 років, сенсибілізованих до домашніх пилових кліщів, є ефективним і безпечним методом лікування і дозволяє швидко (протягом перших 6 місяців SLIT) контролювати симптоми. Дані порівняльного аналізу в групі пацієнтів, які не отримували SLIT, вказують на високу частоту виникнення симптомів хвороби після закінчення базової терапії.
Ключові слова: сублінгвальна алерген-специфічна імунотерапія, діти, бронхіальна астма, алергічний риніт, сенсибілізація, алергени, Діатер.
ОСОБЕННОСТИ ЛЕЧЕНИЯ ДЕТЕЙ ДОШКОЛЬНОГО ВОЗРАСТА, СЕНСИБИЛИЗИРОВАННЫХ АЛЛЕРГЕНАМИ ДОМАШНЕЙ ПЫЛИ
Шарикадзе Е.В.
Это исследование определило эффективность сублингвальной аллерген-специфической иммунотерапии (SLIT) украинских детей моложе 5 лет с аллергическим ринитом и бронхиальной астмой, сенсибилизированных к аллергенам пылевых клещей. Методы. Проспективное исследование когорты проводилось в течение двух лет с оценкой сенсибилизации к ингаляционным аллергенам, измеренной in-vivo по размеру волдырей и количеству положительных реакций на стандартном тесте на коже (SPT). Для анализа статистики использовался пакет SPSS. Результаты. Обследованы 125 детей (средний возраст 4,11 ± 0,83 лет) с атопической астмой и/или аллергическим ринитом, которые были сенсибилизированы к домашним пылевым клещам Dermatophagoides pteronyssinus и/или Dermatophagoides farina. 47 детей получили двухлетний курс SLIT с использованием стандартизованного экстракта сублингвальных аллергенов, содержащих смесь клещей домашней пыли (Der. Pteronyssinus и Der. Farinae) в соотношении 1 (0,175 НЕР): 1 (0,175 НЕР) (Диатер, Испания). Пациенты были моносенсибированы Dermatophagoides pteronyssinus и/или Dermatophagoides farina или были полисенсибилизированы (по SPT), однако симптомы развивались только на домашнюю пыль. В этой группе оценка клинической эффективности SLIT показала значительные различия до лечения и через 6 месяцев после его получения. Симптом «носовой обструкции» оценивался как 2,3 ± -1,6 балла в начале терапии и уменьшались почти в два раза (1,3 ± -1,1); Р <0,05 после 6 месяцев SLIT. Затем (12 и 24 месяца) он снизился до 0,91 ± 0,9 и 0,34 ± 0,5; Р <0,01, соответственно. Вывод. Исследование показало, что использование SLIT при атопической астме или/или аллергическом рините детей до 5 лет, сенсибилизированных к домашним пылевым клещам, является эффективным и безопасным методом лечения и позволяет быстро (в течение первых 6 месяцев SLIT) контролировать симптомы. Данные сравнительного анализа в группе пациентов, которые не получали SLIT, указывают на высокую частоту появления симптомов болезни после окончания базовой терапии.
Ключевые слова: сублингвальная аллерген-специфическая иммунотерапия, дети, бронхиальная астма, аллергический ринит, сенсибилизация, аллергены, Диатер.
References
Shupyk National Medical Academy of postgraduate education,Ukrainian Center for Scientific Medical Information and Patent License Activities. (2011). Algoritm vidboru pacientiv dlya allergenspecificheskoy imunoterapii (ASIT) [Algorithm for selecting patients for allergen specific immunotherapy (ASIT)] Guidelines, Kiev, P.311
Ohotnikova, Е. (2008). Allergicheskiy marsh: svyaz pocoleniy e escalaciya allergii u detey [The allergic march: generations and escalation of allergies in children] Clinical Immunology Allergology Infectology, vol.4 (15).
Pavlova, K. (2012). Patogeneticheskaya terapia allergicheskaya zabolevaniy: vozmojnosty ASIT v Rossii. Effectivnay farmacoterapiya [Pathogenetic therapy of allergic diseases: ASIN opportunities in Russia. Effective pharmacotherapy]. Allergology and Immunology, vol.2, pp. 54-58.
Sepiashvili, R., (2014). Consensus WAO-ARIA-GA2LEN po moleculyrnoy diagnostike allergii. Memorandum Vsemirnoy organizacii po allergii [Consensus WAO-ARIA-GA2LEN molecular diagnosis of allergies. Memorandum of the World Allergy Organization]. Allergology and Immunology, vol., pp. 5-17.
Barberi, S., Ciprandi, G., Verdbci, E. (2015). Effect of high-dose sublingual immunotherapy on respiratory infections in children allergic to house dust mite. Asia Pac Allergy, Vol. 5. -P 163–169.
Bousquet, J., Heinzerling, L., Bachert, C. (2012). Position Paper EAACI Practical guide to skin prick tests in allergy to aeroallergens Allergy. Vol. 67. -P 18–24.
Ciprandi, G., Tosca, M.A., Fasce, L. (2006). Allergic children have more numerous and severe respiratory infections than non-allergic children. Pediatr Allergy Immunol, Vol.17.- Р.389–391.
Ciprandi, G., C. Incorvaia, I., Dell'Albani, Di Cara,. Barberi, S., Puccinelli, P., Frati, F. (2013). RINOBIT Study Group. Allergen immunotherapy may exert an extra-anti-allergic activity in children . J Biol Regul Homeost Agents. Vol.27.- P. 1053–1057.
Canonica, G.W. (2014). Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J., Vol.7. -4-18.
Cox, L. (2001). Sublingual immunotherapy for aeroallergens: status in the United States . Allergy Asthma Proc. Vol. 35. – P.34–42.
Dhami, S., Dhami, S., Nurmatov, U. (2016). Allergen Immunotherapia for allergic asthma protocol for a systematic rewiew. Clin Transl Allergy. Retrieved from: http://ctajournal.biomedcentral.com.
Kusel, M.M., Kebadze, T., Johnston, S.L., Holt, P.G., Sly, P.D. (2012). Febrile respiratory illnesses in infancy and atopy are risk factors for persistent asthma and wheeze. Eur Respir J. Vol. 39. - P. 876–882.
Linkov, G., Toskala, E. (2014). Sublingual immunotherapy: what we can learn from the European experience. Curr Opin Otolaryngol Head Neck Surg. Vol.22. – P. 208–210.
Papadopoulos, N.G., Arakawa, H., Carlsen, K.H. (2012). Position Paper International consensus on (ICON) pediatric asthma . Allergy. Vol.67.P.976-997
Szefler, S.J. (2014). Advances in pediatric asthma in 2013: coordinating asthma care. J Allergy Clin. Vol.14.- P324-325
Wahn, V. (2000). What drives the allergic march? Allergy. Vol. 55. – P. 591-599.
"Inter Collegas" is an open access journal: all articles are published in open access without an embargo period, under the terms of the CC BY-NC-SA (Creative Commons Attribution ‒ Noncommercial ‒ Share Alike) license; the content is available to all readers without registration from the moment of its publication. Electronic copies of the archive of journals are placed in the repositories of the KhNMU and V.I. Vernadsky National Library of Ukraine.
Copyright Agreement
1. This Agreement on the transfer of rights to use the work from the Co-authors to the publisher (hereinafter the Agreement) is concluded between all the Co-authors of the work, represented by the Corresponding Author, and Kharkiv National Medical University (hereinafter the University), represented by an authorized representative of the Editorial Board of scientific journals (hereinafter the Editorial Board).
2. This Agreement is an accession agreement within the meaning of clause 1 of Article 634 of the Civil Code of Ukraine: that is, a contract, "the terms of which are established by one of the parties in forms or other standard forms, which can be concluded only by joining the other party to the proposed contract as a whole. The other party cannot offer its terms of the contract." The party that established the terms of this contract is the University.
3. If there is more than one author, the authors choose the Corresponding Author, who communicates with the Editorial Board on his own behalf and on behalf of all Co-authors regarding the publication of a written work of a scientific nature (article or review, hereinafter referred to as the Work).
4. The contract begins from the moment of submission of the manuscript of the Work by the Corresponding Author to the Editorial Board, which confirms the following:
4.1. all Co-authors of the Work are familiar with and agree with its content, at all stages of reviewing and editing the manuscript and the existence of the published Work;
4.2. all Co-authors of the Work are familiar with and agree to the terms of this Agreement.
5. The published Work is in electronic form in public access on the websites of the University and any websites and electronic databases in which the Work is posted by the University and is available to readers under the terms of the "Creative Commons" license (Attribution NonCommercial Sharealike 4.0 International)" or more free licenses "Creative Commons 4.0".
6. The Corresponding Author transfers, and the University receives, the non-exclusive property right to use the Work by placing the latter on the University's websites for the entire term of copyright. The University participates in the creation of the final version of the Work by reviewing and editing the manuscript of the article or review provided to the Editorial Board by the Corresponding Author, translating the Work into any languages. For the participation of the University in the finalization of the Work, the Co-authors agree to pay the invoice issued to them by the University, if such payment is provided by the University. The size and procedure of such payment are not the subject of this contract.
7. The University has the right to reproduce the Work or its parts in electronic and printed forms, to make copies, permanent archival storage of the Work, distribution of the Work on the Internet, repositories, scientometric databases, commercial networks, including for monetary compensation from third parties.
8. The co-authors guarantee that the manuscript of the Work does not use works whose copyright belongs to third parties.
9. The authors of the Work guarantee that at the time of submission of the manuscript of the Work to the Editorial Board, the property rights to the Work belong only to them, neither in whole nor in part have they been transferred to anyone (not alienated), they are not the subject of a lien, litigation or claims by third parties.
10. The Work may not be posted on the University's website if it violates a person's right to the privacy of his personal and family life, harms public order and health.
11. The work may be withdrawn by the Editorial Board from the University websites, libraries and electronic databases where it was placed by the Editorial Board, in cases of detection of violations of the ethics of the authors and researchers, without any compensation for the losses of the Co-authors. At the time of submission of the manuscript to the Editorial Board and all stages of its editing and review, the manuscript must not have already been published or submitted to other editorial offices.
12. The right transferred under this Agreement extends to the territory of Ukraine and foreign countries.
13. The rights of Co-authors include the requirement to indicate their names on all copies of the Work or during any public use or public mention of the Work; the requirement to preserve the integrity of the Work; legal opposition to any distortion or other encroachment on the Work, which may harm the honor and reputation of the Co-authors.
14. Co-authors have the right to control their personal non-property rights by familiarizing themselves with the text (content) and form of the Work before its publication on the University's website, when transferring it to a printing company for reproduction or when using the Work in other ways.
15. The Co-authors, in addition to the property rights not transferred under this Agreement and taking into account the non-exclusive nature of the rights transferred under this Agreement, retain the property rights to finalize the Work and to use certain parts of the Work in other works created by the Co-authors.
16. The Co-authors are obliged to notify the Editorial Board of all errors in the Work, discovered by them independently after the publication of the Work, and to take all measures to eliminate such errors as soon as possible.
17. The University undertakes to indicate the names of the Co-authors on all copies of the Work during any public use of the Work. The list of Co-authors may be shortened according to the rules for the formation of bibliographic descriptions determined by the University or third parties.
18. The University undertakes not to violate the integrity of the Work, to agree with the Corresponding Author on all changes made to the Work during processing and editing.
19. In case of violation of their obligations under this Agreement, its parties bear the responsibility defined by this Agreement and the current legislation of Ukraine. All disputes under the Agreement are resolved through negotiations, and if the negotiations do not resolve the dispute – in the courts of the city of Kharkiv.
20. The parties are not responsible for the violation of their obligations under this Agreement, if it occurred through no fault of theirs. The party is considered innocent if it proves that it has taken all measures dependent on it for the proper fulfillment of the obligation.
21. The Co-authors are responsible for the truthfulness of the facts, quotes, references to legislative and regulatory acts, other official documentation, the scientific validity of the Work, all types of responsibility to third parties who have claimed their rights to the Work. The co-authors reimburse the University for all costs caused by claims of third parties for infringement of copyright and other rights to the Work, as well as additional material costs related to the elimination of identified defects.